Trials / Terminated
TerminatedNCT01824394
nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
reMARQable nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 481 (actual)
- Sponsor
- Biosense Webster, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate safety and effectiveness of nMARQ Catheter System \[nMARQ\] compared with THERMOCOOL® Navigational Family of catheters in treating subjects with drug-refractory symptomatic paroxysmal atrial fibrillation (PAF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | nMARQ Navigation Catheters | |
| DEVICE | NaviStar ThermoCool Catheters |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2017-11-26
- Completion
- 2017-11-26
- First posted
- 2013-04-04
- Last updated
- 2025-02-04
- Results posted
- 2018-12-12
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT01824394. Inclusion in this directory is not an endorsement.